IMMUPHARMA PLC — Capital/Financing Update 2015

Jan 27, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1727D

Immupharma PLC

27 January 2015

FOR IMMEDIATE RELEASE: FULL RNS                                                                          27 JANUARY 2015

IMMUPHARMA

Advance Assurance Received from H M Revenue and Customs Regarding

"Enterprise Investment Scheme" Status

ImmuPharma PLC (AIM: IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received advance assurance from H M Revenue and Customs that it would qualify for Enterprise Investment Scheme (EIS) status.

EIS offers a range of tax reliefs to investors who invest in qualifying companies.  These tax reliefs would be available provided that the individual and the Company continue to meet the rules of the Scheme at the time of the investment and for a period of 3 years subsequently.

Commenting on the agreement, Richard Warr, ImmuPharma's Executive Chairman, said: "We are pleased to have received this advanced assurance from HM Revenue and Customs.  Qualifying for EIS gives ImmuPharma access to the broadest range of potential investors and investment funds."

ENDS

For further information please contact:

ImmuPharma plc	+ 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer
Dr Robert Zimmer, President and Chief Scientific Officer
Richard Warr, Chairman Tracy Weimar, Vice President, Operations and Finance
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD & Broker	+44 (0) 20 7886 2500
Hugh Morgan Fred Walsh Duncan Monteith

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAXFKADSSEFF